Katy Perry's Space Capsule Will Feature 'Dentist-Style Chairs' and Mood Lighting
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links."
The historic Blue Origin flight launches into space on April 14, featuring an all-female crew consisting of Katy Perry, Lauren Sánchez, Gayle King, Aisha Bowe, Amanda Nguyen, and Kerianne Flynn.
While singer Perry and journalist Sánchez are committed to getting glam for their expedition, the ship itself has some major style points.
The star-studded crew is embarking on Mission NS-31 aboard Blue Origin's New Shepard capsule. The capsule's design was led by Seattle-based design consultancy Teague, the same firm responsible for the Boeing 787 Dreamliner. As reported by GeekWire, the aesthetic of the New Shepard capsule is on par with aircraft like the Dreamliner.
The capsule cabin is "about the size and shape of a big igloo," according to GeekWire, with enough room for six passengers. Crew members sit in dentist-style chairs that can be customized with extra padding to accommodate different body types. Each chair is conveniently located by a 4-foot window for unparalleled space views, while a display screen "about the size of an Amazon Kindle Fire tablet" is mounted on the window's edge, displaying flight data views from external cameras. Cool blue mood lighting sets the tone for an out-of-this-world trip, which may provide potential benefits such as increased alertness and stress-reducing properties.
During the 11-minute spaceflight, the famous passengers will feel three Gs of acceleration on the way up and around four minutes of zero-G at the top, which allows for free floating. The ship was designed with cushioned walls, adding extra comfort and protection, preventing any injury during fluctuations in weightlessness.
In the days before the launch, Perry, Sánchez, King, Bowe, Nguyen, and Flynn will attend final training sessions at the Van Horn, Texas launch site. Though we'll be staying on solid ground, we can't wait for takeoff.
Follow on Instagram and TikTok.
You Might Also Like
15 Home Bar Gifts Every Cocktail Enthusiast Will Appreciate
32 Low Light Indoor Plants That Can Survive in the Darkest Corners of Your Home
These Are the 50 Best Paint Colors for Your Living Room
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
25 minutes ago
- Business Upturn
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median of 23 months through the latest follow-up, demonstrating the potential of lonvo-z to become the first one-time therapy for most HAE patients Lonvo-z was well tolerated and continues to demonstrate a favorable safety profile The global Phase 3 HAELO trial of lonvo-z has concluded screening ahead of schedule with more than half screened from U.S. sites; Intellia to provide an update on enrollment in the future CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom. 'Today's results underscore the promising potential of Intellia's approach to gene editing therapy – a one-time treatment that was well tolerated and offered a highly differentiated, durable effect for patients suffering from a serious disease,' said Intellia President and Chief Executive Officer John Leonard, M.D. 'Seeing all 10 patients in the Phase 1 portion of this study free from both HAE attacks and chronic therapy at nearly two years of median follow-up is incredibly encouraging. These data fuel our optimism for the outcomes of our ongoing Phase 3 HAELO study, which we expect to report in the first half of 2026, and highlight the strong value we believe it will offer patients, physicians and payers.' 'People living with HAE often report a reduced quality of life because they worry about the likelihood of their next attack, either because they still experience attacks or are reminded of it by their use of chronic therapy,' said Dr. Joshua Jacobs, Medical Director, Allergy and Asthma Clinical Research, Inc. 'Based on the data, it is reasonable to expect lonvo-z could offer patients the potential to be free from both physical HAE attacks and the burden of managing chronic HAE treatment.' In the Phase 1 portion of the study, a one-time dose of 25 mg (N=3), 50 mg (N=4) or 75 mg (N=3) of lonvo-z was administered via intravenous infusion and plasma kallikrein protein levels were measured along with HAE attacks. At the time of the February 12 data cutoff, patients were attack-free and treatment-free for a median of nearly two years. With up to three years of follow-up, a single dose of lonvo-z led to a mean reduction in monthly HAE attack rate of 98% over the study period, compared to pre-treatment baseline. For all 10 patients, deep, dose-dependent and durable reductions in plasma kallikrein protein continued to be observed through the latest assessment. Safety Across all three dose levels, lonvo-z has been well tolerated and continues to demonstrate a favorable safety profile consistent with earlier data presented at EAACI in 2024. The most frequent adverse events during the study period were infusion-related reactions (IRRs). IRRs were mostly Grade 1 and resolved with all patients receiving the full dose. With up to 3 years of follow-up, no treatment-emergent serious adverse events were observed, and no treatment-related adverse events were observed during the period following 28 days after dosing. Clinical Development Plans Intellia's global Phase 3, randomized, double-blind, placebo-controlled HAELO trial is ongoing to assess the safety and efficacy of lonvo-z at the 50 mg dosage. The Company announced today the HAELO trial has successfully completed screening ahead of schedule, with over half of the patients being screened in the United States. The study is no longer recruiting and Intellia will provide an update on enrollment in the future. New and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study is planned to be presented in the second half of 2025. Intellia expects to submit a biologics license application (BLA) in 2026 to support the Company's plans for a U.S. launch in 2027. For more information on HAELO (NCT06634420), please visit About the Lonvoguran Ziclumeran (lonvo-z, also known as NTLA-2002) Clinical Program Intellia's ongoing Phase 1/2 study is evaluating the safety and efficacy of lonvo-z in adults with Type I or Type II hereditary angioedema (HAE). The Phase 1 portion of the study is an international, open-label study designed to identify the dose level of lonvo-z selected for further evaluation in the Phase 2 portion of the study. Enrollment in both portions of the Phase 1/2 study is complete. Intellia dosed the first patient in the global Phase 3, randomized, double-blind, placebo-controlled HAELO trial in January of 2025. Visit (NCT05120830) for more details. About Lonvo-z Based on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an investigational in vivo CRISPR-based gene editing therapy designed to prevent HAE attacks by inactivating the kallikrein B1 ( KLKB1 ) gene, which encodes for prekallikrein, the kallikrein precursor protein. Interim Phase 1/2 clinical data showed dramatic reductions in attack rate, as well as consistent, deep and durable reductions in kallikrein levels. Lonvo-z has received five notable regulatory designations, including Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission. About Intellia Therapeutics Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia's deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at and follow us @intelliatx. Forward-Looking Statements This press release contains 'forward-looking statements' of Intellia Therapeutics, Inc. ('Intellia' or the 'Company') within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's beliefs and expectations concerning: the safety, efficacy, success and advancement of its clinical programs for lonvoguran ziclumeran or 'lonvo-z' (also known as NTLA-2002) for hereditary angioedema ('HAE'), including the ability to successfully complete its global Phase 3 HAELO study; its expectation to present additional data regarding lonvo-z, including reporting outcomes of the Phase 3 HAELO study in the first half of 2026 and presenting new and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study of lonvo-z in the second half of 2025; and its expectation to be able to support a biologics license application for lonvo-z for the treatment of HAE by 2026 for a U.S. launch in 2027. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to Intellia's relationship with third parties, including its contract manufacturers, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to valid third party intellectual property; risks related to Intellia's relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies' evaluation of regulatory filings and other information related to our product candidates, including lonvo-z; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical trials, including our ability to complete the Phase 3 HAELO study for HAE; the risk that any one or more of Intellia's product candidates, including lonvo-z, will not be successfully developed and commercialized; and the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or Intellia's other product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia's actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in Intellia's most recent annual report of Form 10-K and quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Intellia's other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law. Intellia Contacts: Investors:Brittany ChavesSenior Manager, Investor Relations [email protected]
Yahoo
an hour ago
- Yahoo
Amazon-ULA rocket launch from Cape Canaveral, Florida, may be visible in Fort Myers, Cape Coral
A rocket launch from Florida could potentially blast off on Monday, June 16, and be visible outside of the Sunshine State. United Launch Alliance will launch the second batch of Amazon satellites into space — and it's possible people can see the Atlas V rocket far outside of Florida. When ULA launches its massive rocket, depending on cloud cover, Floridians (and visitors) as far as Jacksonville, Cape Coral and Miami could see it light up the sky after liftoff from Cape Canaveral Space Force Station. Visibility from most of Florida is possible, according to ULA. What's on board ULA Atlas V? Amazon founder Jeff Bezos' Project Kuiper, a global network of satellites, to compete with SpaceX founder-billionaire Elon Musk and Starlink satellites. This will be the second launch of the Amazon Project Kuiper production satellites, courtesy of the ULA Atlas V rocket. Online, the mission has been called the "Amazon rocket launch" or "the Amazon rocket launch from Florida." Technically, it's an "Amazon-ULA rocket launch" or "Amazon satellite launch." Bezos also founded the private space company Blue Origin, which launches rockets at a facility in Texas and in Cape Canaveral. ➤ Business is booming: Florida's Space Coast is one of fastest-growing economies in U.S. In Florida, we can best see the "Amazon satellite launch" in person, particularly if you're anywhere on the Space Coast (Melbourne, Florida, area), the Fun Coast (Daytona Beach area) or the Treasure Coast (Vero Beach, Jensen Beach and Fort Pierce). Below is more information about the rocket launch in Florida and suggestions on where to watch them from here. Rocket launch tally: Here's a list of all 2025 missions from Cape Canaveral, Florida (psst, there's a lot) For questions or comments, email FLORIDA TODAY Space Reporter Rick Neale at rneale@ or Space Reporter Brooke Edwards at bedwards@ For more space news from the USA TODAY Network, visit Tom Cruise and untitled SpaceX project: 'Mission: Impossible' star who lives in Florida may shoot a film in outer space Mission: United Launch Alliance will launch an Atlas V rocket carrying Amazon's second batch of broadband satellites for its Project Kuiper constellation. Amazon's Project Kuiper is Jeff Bezos' attempt to compete with SpaceX founder Elon Musk's Starlink satellite mission. Launch window: 1:25 p.m. ET Monday, June 16, 2025 Launch location: Launch complex 41 at Cape Canaveral Space Force Station in Cape Canaveral, Florida Sonic booms: No Trajectory: Northeast − it's possible the ULA Atlas V rocket will be visible outside of Florida after liftoff, from Cape Canaveral to New Jersey. Live coverage starts two hours minutes before liftoff at : You can watch live rocket launch coverage from USA TODAY Network's Space Team, which consists of FLORIDA TODAY space reporters Rick Neale and Brooke Edwards and visuals journalists Craig Bailey, Malcolm Denemark and Tim Shortt. Our Space Team will provide up-to-the-minute updates in a mobile-friendly live blog, complete with a countdown clock, at starting 90 minutes before liftoff. You can download the free FLORIDA TODAY app, which is available in the App Store or Google Play, or type into your browser. Shown is the National Weather Service-Melbourne radar, which shows conditions in real-time for the Space Coast, Brevard County, Orlando and other parts of Florida. The current date and time show up on the bottom right of this radar embed; otherwise, you may need to clear your cache. ULA provided a helpful graphic (see above) that shows the Atlas V launch of Kuiper 2 for Amazon and its intended flight path and launch visibility. Note: Cities in the Space Coast of Florida, which is in Brevard County and measures 72 miles of coast, include Titusville, Mims, Port St. John, Merritt Island, Cocoa, Cocoa Beach, Melbourne, West Melbourne, Palm Bay, Satellite Beach, Indian Harbour Beach, Indialantic, Melbourne Beach, Grant-Valkaria and Sebastian. Launch, Space Coast, east Orlando, near University of Central Florida, Bithlo, the northern part of the Treasure Coast, Indian River County, Sebastian, Vero Beach, parts of Daytona Beach, New Smyrna Beach and Oak Hill 1: Launch + 30 seconds, Space Coast, Orlando, the Treasure Coast, Indian River County, Sebastian, Vero Beach, Daytona Beach, New Smyrna Beach and Oak Hill, Volusia County, St. Augustine, Ocala, Lakeland area 2: Launch + 90 seconds, which includes PLF Jettison or separation and jettison of the payload fairing: Space Coast, Daytona Beach, New Smyrna Beach, Oak Hill, Port Orange, Volusia County, Treasure Coast, Indian River County, Martin County, St. Lucie County, Orlando, Sanford, Kissimmee, Central Florida, Ocala, Lakeland, St. Augustine, Ponte Vedra Beach 3: Launch + 150 seconds, which includes solid rocket booster jettison, visibility extends to Sebring, Winter Haven, Palatka, Gainesville, Jacksonville, Sarasota, Manatee County, Sarasota County, Tampa, St. Petersburg, Cape Coral, Fort Myers, Naples, Collier County, Lee County, Clearwater, West Palm Beach, Lake Worth Beach, Wellington, Jupiter, Mar-a-Lago, Palm Beach, southern Georgia, Savannah, Georgia, parts of the Caribbean, the Bahamas 4: Launch + 210 seconds, which includes booster separation, Tallahassee, Panama City, Panhandle, Big Bend area of Florida; visibility extends beyond Florida to Georgia, South Carolina, parts of North Carolina 5: Launch + 270 seconds, ULA Atlas V rocket launch visibility extends beyond Florida to these other states and cities: Georgia; Savannah, Georgia; Atlanta, Georgia; Columbus, Georgia Alabama; Dothan, Alabama; just outside Birmingham, Alabama Tennessee; Knoxville, Tennessee; just outside Huntsville, Tennessee; just outside Nashville, Tennessee Kentucky South Carolina; Spartanburg, South Carolina North Carolina; High Point, North Carolina; Winston-Salem, North Carolina; Charlotte, North Carolina; Wilmington, North Carolina Virginia; Virginia Beach, Virginia; Richmond, Virginia West Virginia; Charleston, West Virginia Maryland; Washington, Maryland Delaware; Annapolis, Delaware; Dover, Delaware 6: Launch + 330 seconds, ULA Atlas V rocket launch visibility extends beyond Florida to these other states and cities: New Jersey: Trenton, New Jersey; New York, New Jersey Pennsylvania: Philadelphia, Pennsylvania; Harrisburg, Pennsylvania; Pittsburgh, Pennsylvania; Erie, Pennsylvania Ohio: Cleveland, Ohio; Columbus, Ohio; Cincinnati, Ohio; Toledo, Ohio Indiana: just outside Indianapolis, Indiana; Fort Wayne, Indiana Michigan: Detroit, Michigan Kentucky: just outside Louisville, Kentucky Rhode Island: Providence, Rhode Island Connecticut: Hartford, Connecticut Massachusetts: Boston, Massachusetts New York: Binghamton, New York; Albany, New York 7: Launch + 390 seconds, visibility of Atlas V rocket may be possible in these states: Alabama Tennessee Kentucky Georgia South Carolina North Carolina Virginia West Virginia Ohio Indiana Michigan Delaware Maryland New Jersey Pennsylvania New York Rhode Island Connecticut Massachusetts New Hampshire Vermont Maine Toronto, Canada The above guidelines are estimates based on the graphic provided by ULA. Sangalang is a lead digital producer for USA TODAY Network. Follow her on Twitter or Instagram at @byjensangalang. Support local journalism. Consider subscribing to a Florida newspaper. This article originally appeared on Fort Myers News-Press: Florida rocket launch: Will Atlas V be seen in Fort Myers after liftoff
Hypebeast
12 hours ago
- Hypebeast
BTS' J-Hope Dazzles With Custom Iced-Out Alex Moss NY Chain
Summary BTS'sJ-Hope, known for his dynamic stage presence and impeccable style, recently turned heads with a show-stopping piece of jewelry during a high-profile performance. The global music icon showcased a bespoke, iced-out chain meticulously crafted by renowned New York-based jewelerAlex Moss NY, a piece that carries the distinctive artistic signature of Japanese graphic designerVERDY. This isn't just any chain; it's a testament to the escalating artistry in custom hip-hop and celebrity jewelry. Alex Moss NY has become a go-to for A-list clientele, celebrated for pushing boundaries with intricate, diamond-encrusted creations that are as much sculptures as they are accessories. His work for artists like Drake and Tyler, the Creator has cemented their reputation for audacious, high-carat designs that perfectly reflect their wearers' unique personas. The involvement of VERDY elevates this piece into a true cultural artifact. VERDY, the creative force behind hugely popular brands like Girls Don't Cry and Wasted Youth, is celebrated for his vibrant, playful, yet sophisticated graphic style, often blending Japanese streetwear aesthetics with Western influences. The integration of his famous Vick character and design vision is translated into an 'iced-out' chain by Alex Moss that signals a powerful cross-pollination of creative worlds. While specific details about the chain's design (e.g., carats, gold type, specific Verdy motifs) will likely emerge in closer looks, one-of-a-kind piece is blinged out in silver, gold, pink and blue gem stones. It speaks to the meticulous craftsmanship of Alex Moss and the distinct artistic flair of Verdy, all brought to life through J-Hope's global platform. This collaboration underscores a significant trend: the fusion of high-end jewelry with graphic art and pop culture. J-Hope wore the piece for his final show at the Goyang Sports Complex Main Stadium in Gyeonggi Province in South Korea for his 'Hope on Stage Tour.' The show was a spectacle for BTS fans, with Jung Kook making a surprise appearance during J-Hope's solo track 'i wonder…' and alter Jin took the stage in a separate encore segment. RM, Jimin, V and SUGA were spotted in the audience as well. Take a closer look at the necklace above and below. [#오늘의방탄]613 행복한 하루였어요!다시 꺼내보아도 반짝일 오늘, 잘 간직할게요💜#오늘의제이홉#제이홉#jhope#BTS#방탄소년단#HOPE_ON_THE_STAGE_TOUR_FINAL#HOS_TOUR_FINAL#jhope_TOUR# — BTS_official (@bts_bighit)June 13, 2025
